South Korea
· Delayed Price · Currency is KRW DAE HWA Pharmaceutical Statistics
Total Valuation
DAE HWA Pharmaceutical has a market cap or net worth of KRW 341.57 billion.
| Market Cap | 341.57B |
| Enterprise Value | n/a |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | Jun 27, 2024 |
Share Statistics
DAE HWA Pharmaceutical has 17.52 million shares outstanding.
| Shares Outstanding | 17.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -15.40% |
| Owned by Insiders (%) | 29.75% |
| Owned by Institutions (%) | 2.14% |
| Float | 12.31M |
Valuation Ratios
The trailing PE ratio is 31.57.
| PE Ratio | 31.57 |
| Forward PE | n/a |
| PS Ratio | 2.95 |
| PB Ratio | 4.25 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.68, with a Debt / Equity ratio of 0.62.
| Current Ratio | 0.68 |
| Quick Ratio | 0.39 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 4.44 |
| Debt / FCF | -3.84 |
| Interest Coverage | 1.20 |
Financial Efficiency
Return on equity (ROE) is 11.26% and return on invested capital (ROIC) is 2.64%.
| Return on Equity (ROE) | 11.26% |
| Return on Assets (ROA) | 2.12% |
| Return on Capital (ROIC) | 2.64% |
| Revenue Per Employee | 374.37M |
| Profits Per Employee | 34.94M |
| Employee Count | 308 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 3.99 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +45.31% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +45.31% |
| 50-Day Moving Average | 10,970.80 |
| 200-Day Moving Average | 10,276.60 |
| Relative Strength Index (RSI) | 81.28 |
| Average Volume (20 Days) | 2,389,364 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DAE HWA Pharmaceutical had revenue of KRW 115.31 billion and earned 10.76 billion in profits. Earnings per share was 617.61.
| Revenue | 115.31B |
| Gross Profit | 48.36B |
| Operating Income | 5.94B |
| Pretax Income | 14.67B |
| Net Income | 10.76B |
| EBITDA | 11.73B |
| EBIT | 5.94B |
| Earnings Per Share (EPS) | 617.61 |
Balance Sheet
The company has 9.83 billion in cash and 52.05 billion in debt, giving a net cash position of -42.22 billion or -2,410.05 per share.
| Cash & Cash Equivalents | 9.83B |
| Total Debt | 52.05B |
| Net Cash | -42.22B |
| Net Cash Per Share | -2,410.05 |
| Equity (Book Value) | 83.28B |
| Book Value Per Share | 4,591.03 |
| Working Capital | -22.75B |
Cash Flow
In the last 12 months, operating cash flow was -2.62 billion and capital expenditures -10.93 billion, giving a free cash flow of -13.55 billion.
| Operating Cash Flow | -2.62B |
| Capital Expenditures | -10.93B |
| Free Cash Flow | -13.55B |
| FCF Per Share | -773.73 |
Margins
Gross margin is 41.94%, with operating and profit margins of 5.15% and 9.33%.
| Gross Margin | 41.94% |
| Operating Margin | 5.15% |
| Pretax Margin | 12.72% |
| Profit Margin | 9.33% |
| EBITDA Margin | 10.18% |
| EBIT Margin | 5.15% |
| FCF Margin | -11.75% |
Dividends & Yields
This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 0.77%.
| Dividend Per Share | 150.00 |
| Dividend Yield | 0.77% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 8.22% |
| Buyback Yield | -3.43% |
| Shareholder Yield | -2.66% |
| Earnings Yield | 3.17% |
| FCF Yield | -3.97% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DAE HWA Pharmaceutical has an Altman Z-Score of 2.84. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.84 |
| Piotroski F-Score | n/a |